Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on... see more

Recent & Breaking News (NDAQ:ACRS)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

GlobeNewswire June 21, 2019

Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)

GlobeNewswire June 17, 2019

Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference

GlobeNewswire June 14, 2019

Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference

GlobeNewswire May 24, 2019

Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments

GlobeNewswire May 8, 2019

Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019

GlobeNewswire May 1, 2019

Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis

GlobeNewswire April 25, 2019

Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata

GlobeNewswire April 24, 2019

Aclaris Therapeutics to Attend Upcoming Investor Conference

GlobeNewswire March 27, 2019

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments

GlobeNewswire March 18, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Benzinga.com  March 16, 2019

Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019

GlobeNewswire March 8, 2019

62 Biggest Movers From Yesterday

Benzinga.com  March 5, 2019

Aclaris Therapeutics to Attend Upcoming Investor Conferences

GlobeNewswire January 2, 2019

58 Biggest Movers From Yesterday

Benzinga.com  December 20, 2018

The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Benzinga.com  December 19, 2018

Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials

GlobeNewswire December 17, 2018

Aclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan

GlobeNewswire December 3, 2018

Aclaris Therapeutics to Attend Upcoming Investor Conferences

GlobeNewswire November 28, 2018

Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 27, 2018